MOREPEN LABS share price has zoomed 5% and is presently trading at Rs 142.4.
Meanwhile, the BSE HEALTHCARE index is at 49,558.3 (up 0.5%).
Among the top gainers in the BSE HEALTHCARE index today are LAURUS LABS (up 2.4%) and SUN PHARMA ADV. RES. (up 2.3%).
J.B.Chemicals (down 3.7%) and METROPOLIS HEALTHCARE (down 2.3%) are among the top losers today.
Over the last one year, MOREPEN LABS has moved up from Rs 48.8 to Rs 142.4, registering a gain of Rs 93.6 (up 191.9%).
On the other hand, the BSE HEALTHCARE index has moved up from 43,982.5 to 49,558.3, registering a gain of 12.7% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were LAURUS LABS (up 133.0%), Divis Laboratories (up 60.2%) and Aurobindo Pharma (up 54.4%).
Festive Offer: We're Giving You Savings of Over Rs 17,000
The BSE Sensex is at 72,747.9 (up 0.5%).
The top gainers among the BSE Sensex today are Kotak Bank (up 3.5%) and Indusind Bank (up 2.0%). The most traded stocks in the BSE Sensex are ITC and Kotak Bank.
In the meantime, NSE Nifty is at 22,670.4 (up 0.5%). Trent and Kotak Bank are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved down from 81,790.1 to 72,747.9, registering a loss of 9,042.3 points (down 11.1%).
MOREPEN LABS net profit grew 394.0% YoY to Rs 563 million for the quarter ended June 2026, compared to a profit of Rs 114 million a year ago. Net sales rose 34.1% to Rs 5,701 million during the period as against Rs 4,252 million in April-June 2025.
For the year ended March 2026, MOREPEN LABS reported 19.0% decrease in net profit to Rs 956 million compared to net profit of Rs 1,180 million during FY25. Revenue of the company fell 0.3% to Rs 18,057 million during FY26.
The current Price to earnings ratio of MOREPEN LABS, based on rolling 12 month earnings, stands at 55.5.
Image source: peterschreiber.media/www.istockphoto.com
Equitymaster requests your view! Post a comment on "MOREPEN LABS Gains 5%; BSE HEALTHCARE Index Up 0.5%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!